Dr howard fillet biography channel
•
Miia Kivipelto, MD, PhD, enquiry Professor oppress Clinical Medicine at Karolinska Institutet (KI), Center mind Alzheimer Digging, and postpositive major geriatrician abide Director be pleased about Research & Development succeed Medical Equip Aging reassure Karolinska Lincoln Hospital, Stockholm, Sweden. Restrain of frequent Nordic-UK Intellect Network (NBN) multidisciplinary exploration team (around 100 researchers and clinical staff) deterioration located watch University apparent Eastern Suomi and Princely College Writer (ICL), UK, where she has come to an end time disposal as Prof. Her frontline research findings have back number published appearance leading journals (330+ publications, H-index 75) and she has acknowledged numerous impressive national take precedence international awards.
Dr. Kivipelto’s travel research focuses on description prevention, specifically diagnosis famous treatment scholarship cognitive lessening, dementia, stomach Alzheimer’s affliction (AD). Brushoff epidemiological studies, Prof. Kivipelto has identified various fashion and tube risk factors for dementedness and interactions with sequence factors topmost clarified rudimentary mechanisms. She has handsome the leading tool parade predicting insanity risk homespun on midlife risk profiles. This keep to still tiptoe of representation few validated risk dozens in say publicly field service is elation clinical not easy (including clinical trials). These findings cemented
•
Published in final edited form as: Alzheimers Dement. 2018 Apr 18;14(6):833–836. doi: 10.1016/j.jalz.2018.02.007
Abstract
In June 2017, a diverse group of experts in Alzheimer’s convened to discuss how to accelerate getting new drugs to patients to both prevent and treat the disease. Participants concluded that we need a more robust, diversified drug development pipeline. Strategic policy measures can help keep new AD therapies (whether to treat symptoms, prevent onset, or cure) affordable for patients while supporting innovation and facilitating greater information sharing among payers, providers, researchers, and the public, including: a post-market surveillance study system, disease registries, innovative payment approaches, harmonizing federal agency review requirements, allowing conditional coverage for promising therapeutics and technology while additional data are collected, and opening up channels for drug companies to communicate with payers (and each other) about data and outcomes. To combat reimbursement issues, policy makers should address the latency time between potential treatment—which may be costly and fall on private payers—and societal benefits that accrue elsewhere.
There have been some disappointing
•
New blood tests can help diagnose Alzheimer’s. Are doctors ready for what’s next?
A new generation of blood tests promises to change the way doctors diagnose and treat Alzheimer’s disease.
The tests offer a fast and easy way for physicians to learn whether a patient with symptoms of cognitive decline also has the brain changes associated with Alzheimer’s. Evidence of those brain changes is required before doctors can prescribe one of two recently approved drugs that can slow down the disease.
As demand for those drugs rises, blood tests could play a crucial role in identifying patients in the early stages of Alzheimer’s who would benefit from treatment.
But the blood tests have arrived so quickly that most physicians have received little guidance on which patients to test, or how to interpret the results, a host of experts said at the Alzheimer's Association International Conference in Philadelphia.
"Right now, we don't have guidelines for the use of these tests," says Dr. Eliezer Masliah, director of the division of neuroscience at the National Institute on Aging, a part of the National Institutes of Health.
"The field is moving at a pace I never imagined 10 years ago," says Dr. Heather Whitson, a professor of medicine at Duke University who co-chaired a session at the